Vascular Solutions, Inc. (VASC) news stock charts
Vascular Solutions, Inc. (VASC) Investment Summary:
Vascular Solutions, Inc. (we, us or Vascular) is a medical device company focused on bringing clinically advanced solutions to interventional cardiologists and interventional radiologists worldwide. We were incorporated in the state of Minnesota in December 1996, and we began operations in February 1997. Our main product lines consist of the following: • Hemostat (blood clotting) products, principally consisting of the D-Stat Dry™ hemostat, a topical thrombin-based pad with a bandage used to control surface bleeding, and the D-Stat® Flowable, a thick yet flowable thrombin-based mixture for preventing bleeding in subcutaneous pockets, • Extraction catheters, principally consisting of the Pronto® V3 extraction catheter, a mechanical system for the removal of soft thrombus from arteries, • Vein products, principally cons ... More..."http://secfilings.nasdaq.com/edgar_conv_html%2f2008%2f02%2f05%2f0000897101-08-000253.html#FIS_BUSINESS"VASCULAR SOLUTIONS INC (VASC:NASDAQ)
Snapshot of VASCULAR SOLUTIONS INC (VASC)
|
OPEN
$9.31
|
PREVIOUS CLOSE
$9.40
|
|
|
DAY HIGH
$9.41
|
DAY LOW
$9.23
|
|
|
52 WEEK HIGH
03/8/10 - $9.91
|
52 WEEK LOW
04/1/09 - $5.70
|
|
|
MARKET CAP
155.8M
|
AVERAGE VOLUME 10 D
59.7K
|
|
|
EPS TTM
$0.34
|
SHARES OUTSTANDING
16.7M
|
|
|
VASC Does Not Pay Dividends
|
P/E TTM
27.4x
|
|
| K = Thousands M = Millions B = Billions | ||
Key developments for VASCULAR SOLUTIONS INC (VASC)
Vascular Solutions, Inc. held its earnings conference call. The company intends to make acquisitions. Howard Root, CEO of the company said: In the fourth quarter, we completed additional animal studies with good results with Magna Seal and received excellent physician feedback and support. While we are not projecting international revenue from the magna seal during 2010, we are very encouraged by the potential of this product in the $500 million existing sealing device market. Beyond the Magna Seal, we are exploring several potential accretive acquisitions of products that fit our sales force call point, and we also continue to plan the next-generation development of our Acolysis therapeutic ultrasound device, which addresses a substantial market for peripheral atherectomy. He added: Okay. Yeah, as far as the acquisitions, I emphasized the accretive part because that's what we're looking at doing. We're not looking at buying R&D projects, we're looking at buying products that are essentially on the market or very close to the market that we can put in our sales force bag and generate sales. When we look at, right now, with the Marine Polymer money in the bank, we're over $21 million cash and no debt, and did a phenomenal job building our cash portfolio in 2009, and we expect that to continue in 2010. Even with the stock repurchase plan, that allows us to have some available cash to make acquisitions without getting anywhere close to a debt position. We also have a $10 million line of credit, but I don't see us as tapping into that. In the last year, we've seen a lot more opportunities to acquire products because, as everyone knows, the financing market for small medical device companies has been closed for some time, or it's very difficult unless you have a real blockbuster device to get through.
Vascular Solutions Inc. expected to Report Q1 2010 Results on April 12, 2010. This event was calculated by Capital IQ (Created on February 2, 2010).
Vascular Solutions Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2009. For the quarter, the company reported total revenue of $18,222,000, operating income of $2,228,000, income before tax of $2,216,000, net income of $1,623,000 or $0.10 per diluted share compared to total revenue of $16,404,000, operating income of $1,457,000, income before tax of $1,477,000, net income of $14,684,000 or $0.90 per diluted share for the same quarter year ago. For the year, the company reported total revenue of $68,427,000, operating income of $8,166,000, income before tax of $8,166,000, net income of $5,378,000 or $0.33 per diluted share compared to total revenue of $61,221,000, operating income of $3,015,000, income before tax of $3,128,000, net income of $16,173,000 or $1.01 per diluted share for the previous year. The company provided earnings guidance for first quarter and full year of 2010. For the full year, the company expects net revenue to increase by approximately 12% from 2009 to between $76 million and $78 million. Corresponding net income on a fully-taxed basis is projected to increase to between $0.53 and $0.57 per fully diluted share, including the one-time litigation gain of $0.13 per share which will be recognized in the first quarter. For the first quarter, the company expects net revenue to be between $17.7 million and $18.0 million. Corresponding net income on a fully-taxed basis for the first quarter is expected to be between $0.20 and $0.21 per fully diluted share, including the one-time litigation gain of $0.13 per share.
Vascular Solutions, Inc. financial resources
VASC Competitors
| Company | Last | Change |
| Bovie Medical Corp | $7.58 USD | +0.04 |
| Endologix Inc | $3.61 USD | -0.04 |
| Kensey Nash Corp | $22.27 USD | -0.40 |
| LeMaitre Vascular Inc | $4.73 USD | +0.062 |
| Staar Surgical Co | $3.63 USD | -0.07 |
| Market data is delayed at least 15 minutes. | ||
Industry Analysis
| Valuation | VASC | Industry Range |
| Price/Earnings | 28.5x |
|
| Price/Sales | 2.2x |
|
| Price/Book | 3.8x |
|
| Price/Cash Flow | 29.0x |
|
| TEV/Sales | 2.0x |
|
|
VASC |
||
VASC transactions
| Type Date |
Target |
|
Buyback
January 29, 2010 |
-- |
More Recent Financial News About Vascular Solutions, Inc.
Vascular Solutions 4Q profit falls on taxes
Read article
Vascular Solutions expects profit boost in 2010
Read article
Vascular Solutions to Participate in the RBC Capital Markets 2010 Healthcare Conference
Read article
Vascular Solutions Announces Record Fourth Quarter Results; Net Revenue Increases 11% to Record $18.2 Million; Net Income of $0.10 Per Share
Read article
Vascular Solutions to Participate in the RBC Capital Markets 2010 Healthcare Conference
Read article
Vascular Solutions gets $3.5M payment from lawsuit
Read article
Vascular Solutions Announces Record Fourth Quarter Results; Net Revenue Increases 11% to Record $18.2 Million; Net Income of $0.10 Per Share
Read article
Vascular Solutions expects profit boost in 2010
Read article
Vascular Solutions 4Q profit falls on taxes
Read article
Vascular Solutions Announces Record Fourth Quarter Results; Net Revenue Increases 11% to Record $18.2 Million; Net Income of $0.10 Per Share
Read article
Q4 2009 Vascular Solutions, Inc. Earnings Release - After Market Close
Read article
Vascular Solutions 4Q profit falls on taxes
Read article
VASCULAR SOLUTIONS INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Sta
Read article
Vascular Solutions expects profit boost in 2010
Read article
Vascular Solutions Receives $3.5 Million as Payment of Monetary Judgment in Litigation With Marine Polymer Technologies
Read article
Vascular Solutions gets $3.5M payment from lawsuit
Read article
VASCULAR SOLUTIONS INC Files SEC form 8-K, Other Events
Read article
InPlay: Vascular Solutions receives $3.5 million as payment of monetary judgment in litigation with Marine Polymer Technologies
Read article
Vascular Solutions, Inc. Earnings Call scheduled for Tue, Feb 2
Read article
VASCULAR SOLUTIONS INC Files SEC form 8-K, Change in Directors or Principal Officers
Read article